JP2022500423A5 - - Google Patents
Info
- Publication number
- JP2022500423A5 JP2022500423A5 JP2021513996A JP2021513996A JP2022500423A5 JP 2022500423 A5 JP2022500423 A5 JP 2022500423A5 JP 2021513996 A JP2021513996 A JP 2021513996A JP 2021513996 A JP2021513996 A JP 2021513996A JP 2022500423 A5 JP2022500423 A5 JP 2022500423A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical compositions
- compositions according
- therapeutic agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730837P | 2018-09-13 | 2018-09-13 | |
| US62/730,837 | 2018-09-13 | ||
| PCT/IB2019/001035 WO2020053664A1 (en) | 2018-09-13 | 2019-09-13 | Combination therapy for the treatment of estrogen-receptor positive breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500423A JP2022500423A (ja) | 2022-01-04 |
| JP2022500423A5 true JP2022500423A5 (enExample) | 2022-09-22 |
| JP7441213B2 JP7441213B2 (ja) | 2024-02-29 |
Family
ID=69777646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513996A Active JP7441213B2 (ja) | 2018-09-13 | 2019-09-13 | エストロゲン受容体陽性乳癌の治療のための併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220047563A1 (enExample) |
| EP (1) | EP3849550B1 (enExample) |
| JP (1) | JP7441213B2 (enExample) |
| CN (1) | CN112912078B (enExample) |
| CA (1) | CA3110788A1 (enExample) |
| ES (1) | ES2993363T3 (enExample) |
| TW (1) | TWI841598B (enExample) |
| WO (1) | WO2020053664A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI882964B (zh) | 2018-09-13 | 2025-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2809312A1 (en) * | 2012-01-31 | 2014-12-10 | Novartis AG | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
| WO2014128655A1 (en) * | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| CN110627770A (zh) * | 2013-11-18 | 2019-12-31 | 福马疗法公司 | 作为bet溴域抑制剂的四氢喹啉组成物 |
| WO2016203335A1 (en) * | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| US20180200261A1 (en) * | 2015-07-20 | 2018-07-19 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| US20180153867A1 (en) * | 2016-12-06 | 2018-06-07 | Gilead Sciences, Inc. | Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| WO2018106444A1 (en) * | 2016-12-06 | 2018-06-14 | Gilead Sciences, Inc. | Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent |
| EP3758753A1 (en) * | 2018-02-27 | 2021-01-06 | Pfizer Inc | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
-
2019
- 2019-09-12 TW TW108133098A patent/TWI841598B/zh active
- 2019-09-13 CA CA3110788A patent/CA3110788A1/en active Pending
- 2019-09-13 JP JP2021513996A patent/JP7441213B2/ja active Active
- 2019-09-13 CN CN201980059916.5A patent/CN112912078B/zh active Active
- 2019-09-13 WO PCT/IB2019/001035 patent/WO2020053664A1/en not_active Ceased
- 2019-09-13 EP EP19861171.7A patent/EP3849550B1/en active Active
- 2019-09-13 US US17/275,462 patent/US20220047563A1/en not_active Abandoned
- 2019-09-13 ES ES19861171T patent/ES2993363T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002886A (es) | Terapia de combinacion para el tratamiento de cancer de mama triple negativo. | |
| JP2024507938A5 (enExample) | ||
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| JP2016528162A (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| AR094654A1 (es) | Modulador del receptor de andrógeno y sus usos, método para tratamiento, composición farmacéutica | |
| JP2016528162A5 (enExample) | ||
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| JP2019526595A5 (enExample) | ||
| JP2015528501A5 (enExample) | ||
| JP2024516795A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2024516363A5 (enExample) | ||
| JP2014533277A5 (enExample) | ||
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| TN2012000493A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| JP2006500346A5 (enExample) | ||
| JP2009506054A5 (enExample) | ||
| WO2013071056A3 (en) | Combination drug therapy for the treatment of solid tumors | |
| JP2015517523A5 (enExample) | ||
| JP2014512355A5 (enExample) | ||
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| JP2013511526A5 (enExample) | ||
| JP2017507151A5 (enExample) | ||
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. |